OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$1.23
Market Cap
$416.38M
52W High
$2.56
52W Low
$1.16
ADV30
6,239,812
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
| Sep 2025 | 1,752,000 | — | -17,625,000 | -20,051,000 | 57,596,000 | 32,565,000 | 54,063,000 |
| Jun 2025 | 1,373,000 | — | -13,795,000 | -14,739,000 | 53,594,000 | 27,013,000 | 50,542,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,401,000
Investing CF
$-215,000
Financing CF
$53,557,000
CapEx
$-175,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-427,244,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-66,763,000
Pretax Income TTM
$-71,673,000
Interest Exp TTM
$5,223,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,465,000
EBITDA
$-63,870,000
Free Cash Flow
$-33,665,624
Enterprise Value
$400,896,800
Total Cash
$31,855,000
Total Debt
$33,296,000
Shares Out
338,521,856
Trailing EPS
$-0.24
Book Value
$-0.04
ROE
-660.0%
ROA
-68.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | — | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | — | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | — | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | — | -60,079,000 |
TTM Snapshot
Revenues TTM
$1,136,000
NetIncome TTM
$-12,970,000
OpCashFlow TTM
$0
Assets (Latest)
$82,442,000
Forward EPS
$-0.23
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.23 · call volume: 387 · put volume: 7
Expected Move to 2027-01-15:
±$0.88
(71.54%) —
implied range
$0.35 –
$2.11
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc. | $408.41M | $7.90 | — |
| AUTL | Autolus Therapeutics plc | $407.20M | $1.53 | — |
| IPSC | Century Therapeutics, Inc. | $405.80M | $2.25 | — |
| VACH | Voyager Acquisition Corp./Cayman Islands | $433.00M | $17.11 | — |
| CCCC | C4 Therapeutics, Inc. | $433.42M | $3.92 | — |
News headlines (Yahoo Finance, 1h cache)
How The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst Guidance
2026-06-06 01:05 · Yahoo
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
2026-06-04 15:30 · Yahoo
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
2026-06-03 15:50 · Yahoo
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
2026-06-03 15:39 · Yahoo
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
2026-06-03 15:35 · Yahoo
Ocugen to Participate in Upcoming June Investor and Industry Conferences
2026-06-02 11:03 · Yahoo
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
2026-05-14 20:30 · Yahoo
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
2026-05-13 11:02 · Yahoo
Ocugen (OCGN) Reports Q1 EPS
2026-05-13 06:21 · Yahoo
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?
2026-05-09 00:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.